Compare Stocks Compare stocks with our powerful stock comparison tool. Analyze fundamentals, price performance, and key financial indicators to make informed investment decisions. Our tool lets you compare up to ten stocks side by side based on Performance Charts, Price & Volume, MarketRank™, Analyst Ratings, Sales & Book Value, Profitability & Earnings, Dividends, Debt, Ownership, Headlines, and more. Simply enter up to ten stock symbols (e.g., BAC, JPM, WFC, C, GS) to get started and uncover top investment opportunities. Stocks to Compare Sections All Sections Selected Performance Chart Price & Volume MarketRank Analyst Ratings Sales & Book Value Profitability & Earnings Dividends Debt Ownership Miscellaneous Headlines About Compare NASDAQ:AXGNNASDAQ:LUNGNASDAQ:SMLRNASDAQ:TMCI On This Page Performance ChartPrice & VolumeMarketRank™Analyst RatingsSales & Book ValueProfitability & EarningsDividendsDebtOwnershipMiscellaneousHeadlinesAbout Comparison Ideas Stock Ideas Comparative Price Performance Over Time1 day7 days30 days90 days365 daysCompare Price & VolumeCompanyCurrent Price50-Day Moving Average52-Week RangeMarket CapBetaAvg. VolumeToday's VolumeAXGNAxoGen$11.30+2.1%$15.24$6.34▼$21.00$504.17M1.19467,636 shs580,171 shsLUNGPulmonx$3.09-0.6%$4.98$2.97▼$9.37$124.40M0.65315,703 shs476,476 shsSMLRSemler Scientific$43.39-2.1%$36.17$21.77▼$81.56$483.89M1.33495,379 shs1.08 million shsTMCITreace Medical Concepts$6.09+3.6%$7.14$4.54▼$10.79$383M0.79607,210 shs455,135 shs10 "Recession Proof" Stocks That Will Thrive in Any MarketWhich stocks are likely to thrive in today's challenging market? Enter your email address and we'll send you MarketBeat's list of ten stocks that will drive in any economic environment.Get This Free ReportCompare Price PerformanceCompany1-Day Performance7-Day Performance30-Day Performance90-Day Performance1-Year PerformanceAXGNAxoGen0.00%-5.87%-32.50%-44.96%+76.56%LUNGPulmonx0.00%-6.89%-40.19%-64.17%-61.46%SMLRSemler Scientific0.00%+2.43%+20.30%+4.48%+90.05%TMCITreace Medical Concepts0.00%-12.63%-12.50%-38.81%+13.95%Compare MarketRank™CompanyOverall ScoreAnalyst's OpinionShort Interest ScoreDividend StrengthESG ScoreNews and Social Media SentimentCompany OwnershipEarnings & ValuationAXGNAxoGen3.4136 of 5 stars3.55.00.00.03.22.50.6LUNGPulmonx3.0958 of 5 stars4.33.00.00.01.42.50.6SMLRSemler Scientific2.5513 of 5 stars3.51.00.00.02.62.51.3TMCITreace Medical Concepts2.2615 of 5 stars3.11.00.00.02.34.20.6Compare Analyst ForecastsCompanyConsensus Rating ScoreConsensus RatingConsensus Price Target% Upside from Current PriceAXGNAxoGen 3.00Buy$22.2096.46% UpsideLUNGPulmonx 2.67Moderate Buy$11.59275.17% UpsideSMLRSemler Scientific 3.00Buy$71.0063.63% UpsideTMCITreace Medical Concepts 2.29Hold$10.1666.78% UpsideCurrent Analyst Ratings BreakdownLatest LUNG, AXGN, SMLR, and TMCI Analyst RatingsDateCompanyBrokerageActionRatingPrice TargetDetails5/22/2025LUNGPulmonxCitigroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$6.50 ➝ $4.155/13/2025AXGNAxoGenCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$26.00 ➝ $24.005/9/2025TMCITreace Medical ConceptsUBS GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetNeutral ➝ Neutral$10.00 ➝ $8.605/1/2025LUNGPulmonxCanaccord Genuity GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetBuy ➝ Buy$16.00 ➝ $15.005/1/2025LUNGPulmonxPiper SandlerSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingOverweight ➝ Overweight$10.00 ➝ $9.005/1/2025LUNGPulmonxD. Boral CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingReiterated RatingBuy ➝ Buy$17.00 ➝ $17.004/11/2025TMCITreace Medical ConceptsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$9.50 ➝ $8.003/17/2025AXGNAxoGenLake Street CapitalSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy$30.003/13/2025TMCITreace Medical ConceptsTruist FinancialSubscribe to MarketBeat All Access for the recommendation accuracy ratingLower Price TargetHold ➝ Hold$10.00 ➝ $9.503/10/2025LUNGPulmonxJefferies Financial GroupSubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageBuy3/10/2025LUNGPulmonxMorgan StanleySubscribe to MarketBeat All Access for the recommendation accuracy ratingInitiated CoverageEqual Weight ➝ Equal Weight(Data available from 5/27/2022 forward. View 10+ years of historical ratings with our analyst ratings screener.)Compare Sales & Book ValueCompanyAnnual RevenuePrice/SalesCashflowPrice/CashBook ValuePrice/BookAXGNAxoGen$194.52M2.65N/AN/A$2.22 per share5.09LUNGPulmonx$87.47M1.42N/AN/A$3.09 per share1.00SMLRSemler Scientific$49.23M9.83$2.56 per share16.95$10.45 per share4.15TMCITreace Medical Concepts$210.82M1.82N/AN/A$2.24 per share2.72Compare Profitability & EarningsCompanyNet IncomeEPSTrailing P/E RatioForward P/E RatioP/E GrowthNet MarginsReturn on Equity (ROE)Return on Assets (ROA)Next Earnings DateAXGNAxoGen-$21.72M-$0.15N/AN/AN/A-7.91%-14.91%-7.49%8/14/2025 (Estimated)LUNGPulmonx-$60.84M-$1.44N/AN/AN/A-67.31%-55.36%-33.53%7/30/2025 (Estimated)SMLRSemler Scientific$20.58M-$2.618.84∞N/A72.65%50.77%47.04%8/4/2025 (Estimated)TMCITreace Medical Concepts-$49.53M-$0.85N/AN/AN/A-30.33%-51.12%-26.36%8/5/2025 (Estimated)Latest LUNG, AXGN, SMLR, and TMCI EarningsDateQuarterCompanyConsensus EstimateReported EPSBeat/MissGap EPSRevenue EstimateActual RevenueDetails5/13/2025Q1 2025SMLRSemler ScientificN/A-$0.76N/A-$6.74N/A$8.84 million5/8/2025Q1 2025TMCITreace Medical Concepts-$0.31-$0.25+$0.06-$0.25$52.07 million$52.57 million5/7/2025Q1 2025LUNGPulmonx-$0.37-$0.36+$0.01-$0.36$22.03 million$22.54 millionCompare DividendsCompanyAnnual PayoutDividend Yield3-Year Dividend GrowthPayout RatioYears of Consecutive GrowthAXGNAxoGenN/AN/AN/AN/AN/ALUNGPulmonxN/AN/AN/AN/AN/ASMLRSemler ScientificN/AN/AN/AN/AN/ATMCITreace Medical ConceptsN/AN/AN/AN/AN/ACompare DebtCompanyDebt-to-Equity RatioCurrent RatioQuick RatioAXGNAxoGen0.673.742.47LUNGPulmonx0.407.706.77SMLRSemler ScientificN/A3.143.09TMCITreace Medical Concepts0.514.122.98Compare OwnershipInstitutional OwnershipCompanyInstitutional OwnershipAXGNAxoGen80.29%LUNGPulmonx91.04%SMLRSemler Scientific49.37%TMCITreace Medical Concepts84.08%Insider OwnershipCompanyInsider OwnershipAXGNAxoGen2.78%LUNGPulmonx6.80%SMLRSemler Scientific30.20%TMCITreace Medical Concepts27.72%Compare Miscellaneous StatsCompanyEmployeesShares OutstandingFree FloatOptionableAXGNAxoGen45045.54 million40.93 millionOptionableLUNGPulmonx25040.26 million37.24 millionOptionableSMLRSemler Scientific12011.15 million6.47 millionNot OptionableTMCITreace Medical Concepts25062.89 million47.08 millionOptionableLUNG, AXGN, SMLR, and TMCI HeadlinesRecent News About These CompaniesTMCI LAWSUIT ALERT: Levi & Korsinsky Notifies Treace Medical Concepts, Inc. Investors - Lead Plaintiff Deadline June 10, 2025May 27 at 4:30 PM | accessnewswire.comROSEN, A LEADING LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TMCIMay 27 at 4:12 PM | markets.businessinsider.comClass Action Alert: Levi & Korsinsky Reminds Treace Medical Concepts, Inc. (TMCI) Investors of June 10, 2025 DeadlineMay 27 at 2:40 PM | accessnewswire.comROSEN, A LEADING LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TMCIMay 27 at 2:23 PM | accessnewswire.comInvestors Urged to Contact Levi & Korsinsky for Information Before June 10, 2025 - Treace Medical Concepts, Inc. (TMCI)May 27 at 12:30 PM | accessnewswire.comTMCI ALERT: Levi & Korsinsky Files Securities Fraud Class Action Against Treace Medical Concepts, Inc. - June 10, 2025 DeadlineMay 27 at 11:00 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Treace Medical Concepts, Inc of Class Action Lawsuit and Upcoming Deadlines - TMCIMay 27 at 10:45 AM | accessnewswire.comTreace Medical Concepts, Inc. (TMCI) Class Action Lawsuit: Levi & Korsinsky Reminds Investors of June 10, 2025 DeadlineMay 27 at 9:30 AM | accessnewswire.comSecurities Lawsuit Alert: Treace Medical Concepts, Inc. (TMCI) - Contact Levi & Korsinsky Before June 10, 2025May 27 at 8:45 AM | accessnewswire.comTREACE MEDICAL CONCEPTS, INC. (NASDAQ: TMCI) SHAREHOLDER ALERT Bernstein Liebhard LLP Reminds Treace Medical Concepts, Inc. Investors of Upcoming DeadlineMay 27 at 8:30 AM | globenewswire.comInvestor Alert: Deadline Approaching to Join Treace Medical Concepts, Inc. (TMCI) Class Action - Contact Levi & KorsinskyMay 27 at 7:25 AM | accessnewswire.comTMCI INVESTOR ALERT: Bronstein, Gewirtz and Grossman, LLC Announces that Treace Medical Concepts, Inc. Shareholders with Substantial Losses Have Opportunity to Lead Class Action Lawsuit!May 27 at 7:00 AM | accessnewswire.comRecover Investment Losses: Levi & Korsinsky Files Class Action Against Treace Medical Concepts, Inc. (TMCI)May 26 at 10:30 PM | accessnewswire.comClass Action Alert: Levi & Korsinsky Reminds Treace Medical Concepts, Inc. (TMCI) Investors of June 10, 2025 DeadlineMay 26 at 1:30 PM | accessnewswire.comScott+Scott Attorneys at Law LLP Alerts Investors of The Pending Securities Class Action Against Treace Medical Concepts, Inc. (™CI)May 26 at 12:19 PM | investing.comROSEN, A LEADING INVESTOR RIGHTS LAW FIRM, Encourages Treace Medical Concepts, Inc. Investors to Secure Counsel Before Important Deadline in Securities Class Action - TMCIMay 26 at 12:00 PM | accessnewswire.comJune 10, 2025 Deadline Approaching: Join Class Action Against Treace Medical Concepts, Inc. (TMCI) - Contact Levi & KorsinskyMay 26 at 11:30 AM | accessnewswire.comLevi & Korsinsky Notifies Treace Medical Concepts, Inc. (TMCI) Investors - Lead Plaintiff Deadline on June 10, 2025May 26 at 10:30 AM | accessnewswire.comINVESTOR ALERT: Pomerantz Law Firm Reminds Investors with Losses on their Investment in Treace Medical Concepts, Inc of Class Action Lawsuit and Upcoming Deadlines - TMCIMay 26 at 10:00 AM | prnewswire.comJoin Class Action to Recover Losses from Treace Medical Concepts, Inc. (TMCI) - Contact Levi & Korsinsky Before June 10, 2025May 26 at 7:15 AM | accessnewswire.comBNP Paribas Financial Markets Makes New $590,000 Investment in Treace Medical Concepts, Inc. (NASDAQ:TMCI)May 26 at 3:21 AM | marketbeat.comNew MarketBeat Followers Over TimeMedia Sentiment Over TimeTop HeadlinesView All HeadlinesQualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongBy Sam Quirke | May 13, 2025View Qualcomm Is 5x Cheaper Than AMD, But Won’t Be for LongWhy D-Wave's Project With Davidson Is a Game-Changer For QuantumBy Nathan Reiff | April 30, 2025View Why D-Wave's Project With Davidson Is a Game-Changer For QuantumSuper Micro Computer Stock Clears New Path Higher on Saudi OrdersBy Gabriel Osorio-Mazilli | May 22, 2025View Super Micro Computer Stock Clears New Path Higher on Saudi OrdersUnitedHealth Insiders Double Down: Is UNH Stock a Value Play?By Jeffrey Neal Johnson | May 19, 2025View UnitedHealth Insiders Double Down: Is UNH Stock a Value Play?PepsiCo’s Stock Price Is Disconnected From Reality: Time to BuyBy Thomas Hughes | April 28, 2025View PepsiCo’s Stock Price Is Disconnected From Reality: Time to BuyLUNG, AXGN, SMLR, and TMCI Company DescriptionsAxoGen NASDAQ:AXGN$11.30 +0.23 (+2.08%) Closing price 04:00 PM EasternExtended Trading$11.56 +0.25 (+2.26%) As of 07:14 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.AxoGen, Inc., together with its subsidiaries, develops and commercializes technologies for peripheral nerve regeneration and repair worldwide. The company's products include Avance Nerve Graft, a biologically active off-the-shelf processed human nerve allograft for bridging severed peripheral nerves without the comorbidities associated with a second surgical site; AxoGuard Nerve Connector, a porcine submucosa extracellular matrix (ECM) coaptation aid for tensionless repair of severed peripheral nerves; AxoGuard Nerve Protector, a porcine submucosa ECM product that is used to wrap and protect damaged peripheral nerves, as well as reinforces the nerve reconstruction while preventing soft tissue attachments; and Axoguard HA+ Nerve Protector, a processed porcine submucosa ECM base layer with a hyaluronate-alginate gel coating designed to provide short- and long-term protection for peripheral nerve injuries. Its products also comprise Axoguard Nerve Cap, a porcine submucosa ECM product that is used to protect a peripheral nerve end, as well as separates the nerve from the surrounding environment to reduce the development of symptomatic or painful neuroma; and AxoTouch two-point discriminator, a tool that is used for measuring the innervation density of surface area of the skin. The company provides its products to hospitals, surgery centers, and military hospitals, plastic reconstructive surgeons, orthopedic and plastic hand surgeons, and various oral and maxillofacial surgeons. AxoGen, Inc. is headquartered in Alachua, Florida.Pulmonx NASDAQ:LUNG$3.09 -0.02 (-0.64%) Closing price 04:00 PM EasternExtended Trading$3.08 0.00 (-0.16%) As of 07:38 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Pulmonx Corporation, a commercial-stage medical technology company, provides minimally invasive devices for the treatment of chronic obstructive pulmonary diseases. The company offers Zephyr Endobronchial Valve, a solution for the treatment of patients with hyperinflation associated with severe emphysema; and Chartis Pulmonary Assessment System, a balloon catheter and console system with flow and pressure sensors that are used to assess the presence of collateral ventilation. It also offers StratX Lung Analysis Platform, a cloud-based quantitative computed tomography analysis service that offers information on emphysema destruction, fissure completeness, and lobar volume to help identify target lobes for the treatment with Zephyr Valves. The company serves emphysema patients in the United States, Europe, the Middle East, Africa, the Asia-Pacific, and internationally. The company was formerly known as Pulmonx and changed its name to Pulmonx Corporation in December 2013. Pulmonx Corporation was incorporated in 1995 and is headquartered in Redwood City, California.Semler Scientific NASDAQ:SMLR$43.39 -0.93 (-2.10%) Closing price 04:00 PM EasternExtended Trading$42.98 -0.41 (-0.96%) As of 07:58 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Semler Scientific, Inc. provides technology solutions to enhance the clinical effectiveness and efficiency of healthcare providers in the United States. The company's products include QuantaFlo, a four-minute in-office blood flow test that enables healthcare providers to use blood flow measurements as part of their examinations of a patient's vascular condition. It also offers Insulin Insights, a software program that is used by a healthcare provider to optimize outpatient insulin dosing. The company's products serve cardiologists, internists, nephrologists, endocrinologists, podiatrists, family practitioners, healthcare insurance plans, integrated delivery networks, independent physician groups, and companies contracting with the healthcare industry, such as risk assessment groups and retailers. It offers its products through sales representatives and distributors. The company was incorporated in 2007 and is headquartered in Santa Clara, California.Treace Medical Concepts NASDAQ:TMCI$6.09 +0.21 (+3.57%) Closing price 04:00 PM EasternExtended Trading$6.09 0.00 (0.00%) As of 07:40 PM Eastern Extended trading is trading that happens on electronic markets outside of regular trading hours. This is a fair market value extended hours price provided by Polygon.io. Learn more.Treace Medical Concepts, Inc., a medical technology company, designs, manufactures, and markets medical devices in the United States. The company offers Lapiplasty 3D bunion correction system that combines instruments, implants, and surgical methods designed to surgically correct three planes of the bunion deformity. It also provides Lapiplasty mini-incision system designed to allow the Lapiplasty procedure to be performed through a 3.5cm incision. In addition, the company offers Adductoplasty system designed for reproducible realignment, stabilization, and fusion of the midfoot. Treace Medical Concepts, Inc. was founded in 2013 and is headquartered in Ponte Vedra, Florida. More Stock Comparisions from MarketBeat Stock Comparison Ideas (A-K)5GAgricultureAirlineAmerica FirstApparelArtificial IntelligenceAutomotiveBankBiotechBitcoinBlockchainBlue ChipCanadianCannabisCasinoChatGPTChineseCloud StorageCryptocurrencyCybersecurityDefenseDividendDow 30EcommerceElectric VehiclesEnergyEntertainmenteSportsEV ChargingFertilizerGoldGroceryGrowthHealthcareHigh DividendHotelStock Comparison Ideas (L-Z)Large CapLeisureLithiumMagnificent SevenMega CapMemeMetaverseMid CapMiningMusic IndustryNanotechnologyNFTNuclear EnergyOilPharmaceuticalQuantum ComputingRenewable EnergyRestaurantRetailSemiconductorSocial MediaSolarSpaceTechnologyTelecomToyUtilityVideo GameVirtual RealityWallStreetBets More Stock Ideas from MarketBeat Stock Lists 5G Stocks Biotech Stocks Blue Chip Stocks DOW 30 Stocks FAANG Stocks Gold Stocks Large Cap Stocks Lumber Stocks Marijuana Stocks Micro Cap Stocks Oil Stocks REITs Small Cap Stocks SPACs Travel Stocks Trillion Dollar Stocks Water Stocks Warren Buffett Stocks Low Priced Stocks Penny Stock List Popular Penny Stocks Top Stocks Today Stocks on Sale Stocks Under $0.05 Stocks Under $0.10 Stocks Under $0.25 Stocks Under $0.50 Stocks Under $1 Stocks Under $2 Stocks Under $3 Stocks Under $5 Stocks Under $10 Stocks Under $20 Stocks Under $30 Stocks Under $50 Stocks By Exchange NASDAQ Stocks NYSE Stocks NYSEAMERICAN Stocks NYSEARCA Stocks NYSEMKT Stocks OTCMKTS Stocks TSX Stocks TSXV Stocks LSE Stocks BATS Stocks Latest Stock Ideas Microsoft's Outlook Brightens as Analysts Boost Bullish Ratings Palantir Scores First $1 Billion Contract; Is It Priced In? Tesla: Why Analysts Think It Could Jump Another 47% Bullish NVIDIA Market Set to Surge 50% Ahead of Q1 Earnings Navitas Soars on NVIDIA Deal: Breaking Down Its Tech and Outlook 3 Dividend Stocks to Get You Through Tariff Volatility Apple Sinks After New 25% Tariff Announcement—What's The Bottom? MarketBeat Week in Review – 05/19 - 05/23 Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.
